Perrigo Company Overview

  • Founded
  • 1887

Founded
  • Status
  • Public

  • Employees
  • 9,900

Employees
  • Stock Symbol
  • PRGO

Stock Symbol
  • Investments
  • 49

  • Share Price
  • $37.38

  • (As of Monday Closing)

Perrigo Company General Information

Description

Perrigo Co PLC is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company's product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestitures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma.

Contact Information

Website
www.perrigo.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
NYS
Primary Office
  • The Sharp Building
  • Hogan Place
  • Dublin 2
  • Ireland
+353 (01) 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Perrigo Company Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$37.38 $37.20 $30.78 - $43.90 $5.03B 135M 1.51M -$0.80

Perrigo Company Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 8,432,078 6,676,004 8,814,691 10,133,322
Revenue 4,401,200 4,138,700 4,088,200 3,869,900
EBITDA 345,600 680,500 421,300 562,600
Net Income (107,300) (68,900) (162,600) 146,100
Total Assets 10,677,500 10,425,700 11,488,400 11,301,400
Total Debt 4,111,000 3,693,800 3,725,700 3,369,200
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Perrigo Company Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Perrigo Company‘s full profile, request access.

Request a free trial

Perrigo Company Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Perrigo Co PLC is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The c
Pharmaceuticals
Dublin, Ireland
9,900 As of 2021
000 0000-00-00
000000&0

000000

exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute
000000000000000
Mumbai, India
0000 As of 0000

0000-0

consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolo
000000000000000
Seoul, South Korea
00 As of 0000
000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Perrigo Company Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abbott India Corporation Mumbai, India 0000
0000-0 00000 00000 Corporate Backed or Acquired Seoul, South Korea 00 000000000
000000000000000 00 Corporation Lagos, Nigeria 00
00000000 Corporation Winnipeg, Canada 00 00000 000000000 00000
000000 00000000000 Corporation Montreal, Canada 000 00000 00000000 00000
You’re viewing 5 of 32 competitors. Get the full list »

Perrigo Company Patents

Perrigo Company Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210113698-A1 Bulk polyethylene glycol compositions Pending 18-Oct-2019 000000000 0
US-20210023073-A1 Dextromethorphan extended release pharmaceutical composition Pending 22-Jul-2019 0000000000 0
US-D904182-S1 Carton Active 29-Jun-2018
US-D874261-S1 Carton Active 29-Jun-2018
US-D904181-S1 Carton Active 29-Jun-2018
To view Perrigo Company’s complete patent history, request access »

Perrigo Company Executive Team (40)

Name Title Board Seat Contact Info
Murray Kessler Chief Executive Officer & Board Member
Svend Andersen Executive Vice President & President
Eduardo Bezerra Chief Financial Officer, Finance & Executive Vice President
Thomas Farrington Chief Information Officer & Executive Vice President
Alison Ives Executive Vice President & Chief Scientific Officer
You’re viewing 5 of 40 executive team members. Get the full list »

Perrigo Company Board Members (12)

Name Representing Role Since
0000000 0000000000 Self Board Member 000 0000
000000 0000000 Self Board Member 000 0000
0000000 000000 Perrigo Company Board Member 000 0000
00000 0000 Self Board Member 000 0000
00000000 000000 Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Perrigo Company Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Perrigo Company Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Perrigo Company‘s full profile, request access.

Request a free trial

Perrigo Company Investments & Acquisitions (49)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 (00000 01-Nov-2022 000000000 00000 Buildings and Property
000 000000 29-Apr-2022 0000000000 00.000 Drug Discovery 000000 00
000000 (00000 02-Nov-2020 000000000 Buildings and Property 000000 00
0000000 17-Jun-2020 000000000 0000 Other Pharmaceuticals and Biotechnology 000000 00
High Ridge Brands (Oral Care Assets) 01-Apr-2020 Merger/Acquisition 00000 Personal Products 000000 00
You’re viewing 5 of 49 investments and acquisitions. Get the full list »

Perrigo Company Subsidiaries (5)

Company Name Industry Location Founded
Vedants Drugs and Fine Chemicals Pharmaceuticals Mumbai, India 2004
000 000000 Drug Discovery Paris, France 0000
0000000 000000000 Pharmaceuticals Balcatta, Australia 0000
00000 Other Commercial Products Grand Rapids, MI 0000
0000000 0000000000 Drug Delivery Ciudad Satelite, Mexico 0000
To view Perrigo Company’s complete subsidiaries history, request access »

Perrigo Company ESG

Risk Overview

Risk Rating

Updated September, 11, 2022

36.74 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,613

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,004

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 472

Rank

00.00

Percentile

To view Perrigo Company’s complete esg history, request access »

Perrigo Company Exits (5)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000-00000 000 28-Aug-2015 000000000000000000 000.00 Completed
  • 0000000 0000000
00000000 000000000 11-Feb-2013 000000000000000000 00000 Completed
  • 0000000 0000000
000 000000 0000000 01-Jan-2003 000000000000000000 Completed
  • 0000000 0000000
000000 01-Jan-1997 000000000000000000 Completed
  • 0000000 0000000
Vi-Jon 01-Dec-1994 Merger/Acquisition 0000 Completed
To view Perrigo Company’s complete exits history, request access »